Gilead’s Trodelvy misses goal in bladder cancer study
An accelerated approval for Gilead Sciences’ cancer drug Trodelvy could be in question after the company disclosed Thursday afternoon that a confirmatory trial failed to meet its main objective. In the trial, called TROPiCS-04, Trodelvy did not …